Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

Thalassemia & Sickle Cell Society (TSCS) recently participated in the National Conference organized by the Federation of Blood Donor Organizations of India (FBDOI) and the Indian Red Cross Society ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

A Cherokee County man says he has been successfully cured of Sickle Cell Anemia complications. Kyle Registre, 23, joined a Children's Healthcare of Atlanta gene therapy clinical trial in 2019 ...

Agios Pharmaceuticals Inc (AGIO) reports a 51% increase in net Pyrukynd revenue and outlines promising future launches and ...

Vertex has entered a reimbursement agreement with NHS England enabling eligible SCD patients to access Casgevy in the public health system.

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...